{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:15:17Z","timestamp":1773404117855,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"name":"GenMark Diagnostics"},{"name":"ArcBio"},{"name":"Canta"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sotrovimab is an anti-spike neutralization monoclonal antibody developed to reduce the risk of coronavirus disease 2019 (COVID-19) progression and advancement to hospitalization in high-risk patients. Currently, there is limited research describing the association of sotrovimab treatment in patients with hematologic malignancy and the predictive factors of hospitalization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed an observational study of 156 consecutive cancer patients who received sotrovimab at Memorial Sloan Kettering Cancer Center in New York City during the BA.1 Omicron surge. We evaluated the demographic, clinical, and laboratory characteristics of the patients who had subsequent COVID-19\u2013related hospitalization(s) compared to those who did not.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 156 study patients, 17 (11%) were hospitalized, of whom 4 were readmitted for COVID-19\u2013related complications; 3 deaths were attributed to COVID-19. Results from multivariable logistic regression show that significant factors associated with hospitalization include patients on anti-CD20 therapy (adjusted odds ratio [aOR], 5.59 [95% confidence interval {CI}, 1.73\u201318.12]; P = .004) and with relapse\/refractory disease (aOR, 5.69 [95% CI, 1.69\u201319.16]; P = .005). Additionally, whole genome sequencing of severe acute respiratory syndrome coronavirus 2 detected high occurrences of mutations in the spike gene associated with treatment-related resistance longitudinal samples from 11 patients treated with sotrovimab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in patients with hematologic malignancy when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac916","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T17:09:26Z","timestamp":1669741766000},"page":"1476-1482","source":"Crossref","is-referenced-by-count":5,"title":["Predictors of Coronavirus Disease 2019 Hospitalization After Sotrovimab in Patients With Hematologic Malignancy During the BA.1 Omicron Surge"],"prefix":"10.1093","volume":"76","author":[{"given":"Judy","family":"Yan","sequence":"first","affiliation":[{"name":"Infection Control , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha N","family":"Steiger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rich","family":"Kodama","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Department of Medicine , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Fender","sequence":"additional","affiliation":[{"name":"Infection Control , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]},{"name":"Digital Informatics and Technology Solutions , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Laracy","sequence":"additional","affiliation":[{"name":"Infection Control , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]},{"name":"Infectious Disease Service, Department of Medicine , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]},{"name":"Department of Medicine, Joan and Sanford Weill Medical College of Cornell University , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"McMillen","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krupa","family":"Jani","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth V","family":"Robilotti","sequence":"additional","affiliation":[{"name":"Infection Control , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]},{"name":"Infectious Disease Service, Department of Medicine , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]},{"name":"Department of Medicine, Joan and Sanford Weill Medical College of Cornell University , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N Esther","family":"Babady","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan K","family":"Seo","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Department of Medicine , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]},{"name":"Department of Medicine, Joan and Sanford Weill Medical College of Cornell University , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mini","family":"Kamboj","sequence":"additional","affiliation":[{"name":"Infection Control , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]},{"name":"Infectious Disease Service, Department of Medicine , Memorial Sloan Kettering Cancer Center, New York, New York ,","place":["USA"]},{"name":"Department of Medicine, Joan and Sanford Weill Medical College of Cornell University , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"2024101808043806700_ciac916-B1","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"key":"2024101808043806700_ciac916-B2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"2024101808043806700_ciac916-B3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"key":"2024101808043806700_ciac916-B4","first-page":"1","article-title":"SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2024101808043806700_ciac916-B5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"2024101808043806700_ciac916-B6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"2024101808043806700_ciac916-B7","author":"US Food and Drug Administration"},{"key":"2024101808043806700_ciac916-B8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N Engl J Med"},{"key":"2024101808043806700_ciac916-B9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"key":"2024101808043806700_ciac916-B10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jmoldx.2020.10.018","article-title":"Performance of severe acute respiratory syndrome coronavirus 2 real-time RT-PCR tests on oral rinses and saliva samples","volume":"23","author":"Babady","year":"2021","journal-title":"J Mol Diagn"},{"key":"2024101808043806700_ciac916-B11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/cid\/ciab670","article-title":"Risk of healthcare-associated transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in hospitalized cancer patients","volume":"74","author":"Chow","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024101808043806700_ciac916-B12","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.21105\/joss.03773","article-title":"Nextclade: clade assignment, mutation calling and quality control for viral genomes","volume":"6","author":"Aksamentov","year":"2021","journal-title":"J Open Source Softw"},{"key":"2024101808043806700_ciac916-B13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/2643-3230.BCD-21-0142","article-title":"Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy","volume":"2","author":"Tamari","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2024101808043806700_ciac916-B14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"2024101808043806700_ciac916-B15","doi-asserted-by":"crossref","first-page":"e13901","DOI":"10.1111\/tid.13901","article-title":"Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch","volume":"24","author":"Yetmar","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"2024101808043806700_ciac916-B16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.kint.2022.04.003","article-title":"Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection","volume":"101","author":"Chavarot","year":"2022","journal-title":"Kidney Int"},{"key":"2024101808043806700_ciac916-B17","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/cid\/ciac324","article-title":"Impact of vaccination and early monoclonal antibody therapy on coronavirus disease 2019 outcomes in organ transplant recipients during the Omicron wave","volume":"75","author":"Solera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024101808043806700_ciac916-B18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"key":"2024101808043806700_ciac916-B19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Case fatality rate of cancer patients with COVID-19 in a New York hospital system","volume":"10","author":"Mehta","year":"2020","journal-title":"Cancer Discov"},{"key":"2024101808043806700_ciac916-B20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"key":"2024101808043806700_ciac916-B21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/blood.2021013768","article-title":"Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting","volume":"139","author":"Mittelman","year":"2022","journal-title":"Blood"},{"key":"2024101808043806700_ciac916-B22","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/S2666-5247(22)00120-3","article-title":"Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients","volume":"3","author":"Destras","year":"2022","journal-title":"Lancet Microbe"},{"key":"2024101808043806700_ciac916-B23","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1093\/cid\/ciac601","article-title":"Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the severe acute respiratory syndrome coronavirus 2 Omicron variant","volume":"76","author":"Huygens","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac916\/48908702\/ciac916.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/8\/1476\/59836170\/ciac916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/8\/1476\/59836170\/ciac916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T08:05:04Z","timestamp":1729238704000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/8\/1476\/6850570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,11,29]]},"published-print":{"date-parts":[[2023,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac916","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,15]]},"published":{"date-parts":[[2022,11,29]]}}}